Mannatech (MTEX) Competitors

$4.88 +0.13 (+2.74%)

As of 12:12 PM Eastern

MTEX vs. PLUR, CRVO, NXTC, ATHA, and SKYE

Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Pluri (PLUR), CervoMed (CRVO), NextCure (NXTC), Athira Pharma (ATHA), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does Mannatech compare to Pluri?

Mannatech (NASDAQ:MTEX) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

: Mannatech has a net margin of -14.08% compared to Pluri's net margin of -1,890.59%. Pluri's return on equity of 0.00% beat Mannatech's return on equity.
Company Net Margins Return on Equity Return on Assets
Mannatech -14.08% -398.35% -45.63%
Pluri -1,890.59% N/A -99.68%
: 13.0% of Mannatech shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 25.9% of Pluri shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: In the previous week, Mannatech and Mannatech both had 1 articles in the media. Pluri's average media sentiment score of 2.00 beat Mannatech's score of 0.00 indicating that Pluri is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pluri
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Pluri has a consensus price target of $12.00, suggesting a potential upside of 263.64%. Given Pluri's stronger consensus rating and higher probable upside, analysts plainly believe Pluri is more favorable than Mannatech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Pluri
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Mannatech has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mannatech $108.04M 0.09 -$15.21M -$8.00 N/A
Pluri $1.34M 26.52 -$22.58M -$4.92 N/A
: Mannatech has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-14.08%	-398.35%	-45.63%
Pluri	-1,890.59%	N/A	-99.68%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.09	-$15.21M	-$8.00	N/A
Pluri	$1.34M	26.52	-$22.58M	-$4.92	N/A

Summary

Pluri beats Mannatech on 9 of the 15 factors compared between the two stocks.

How does Mannatech compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

: Mannatech has higher revenue and earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CervoMed $4.01M 8.61 -$26.97M -$2.98 N/A
Mannatech $108.04M 0.09 -$15.21M -$8.00 N/A
: CervoMed presently has a consensus price target of $23.00, suggesting a potential upside of 516.62%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts plainly believe CervoMed is more favorable than Mannatech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CervoMed
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
Mannatech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Mannatech has a net margin of -14.08% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -96.04% beat Mannatech's return on equity.
Company Net Margins Return on Equity Return on Assets
CervoMed -672.80% -96.04% -82.88%
Mannatech -14.08% -398.35% -45.63%
: In the previous week, Mannatech had 1 more articles in the media than CervoMed. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for CervoMed. CervoMed's average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.
Company Overall Sentiment
CervoMed Neutral
Mannatech Neutral
: 25.2% of CervoMed shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 35.4% of CervoMed shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: CervoMed has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	8.61	-$26.97M	-$2.98	N/A
Mannatech	$108.04M	0.09	-$15.21M	-$8.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-96.04%	-82.88%
Mannatech	-14.08%	-398.35%	-45.63%

Company	Overall Sentiment
CervoMed	Neutral
Mannatech	Neutral

Summary

Mannatech beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does Mannatech compare to NextCure?

NextCure (NASDAQ:NXTC) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

: Mannatech has higher revenue and earnings than NextCure. Mannatech is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NextCure N/A N/A -$55.84M -$20.00 N/A
Mannatech $108.04M 0.09 -$15.21M -$8.00 N/A
: NextCure presently has a consensus price target of $23.00, suggesting a potential upside of 146.78%. Given NextCure's stronger consensus rating and higher possible upside, research analysts plainly believe NextCure is more favorable than Mannatech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NextCure
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Mannatech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: NextCure has a net margin of 0.00% compared to Mannatech's net margin of -14.08%. NextCure's return on equity of -152.90% beat Mannatech's return on equity.
Company Net Margins Return on Equity Return on Assets
NextCure N/A -152.90% -109.17%
Mannatech -14.08% -398.35% -45.63%
: In the previous week, NextCure and NextCure both had 1 articles in the media. NextCure's average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NextCure
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 42.7% of NextCure shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: NextCure has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$20.00	N/A
Mannatech	$108.04M	0.09	-$15.21M	-$8.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-152.90%	-109.17%
Mannatech	-14.08%	-398.35%	-45.63%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NextCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NextCure beats Mannatech on 8 of the 13 factors compared between the two stocks.

How does Mannatech compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

: 57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Mannatech has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athira Pharma N/A N/A -$96.94M -$9.68 N/A
Mannatech $108.04M 0.09 -$15.21M -$8.00 N/A
: Athira Pharma presently has a consensus price target of $4.00, indicating a potential downside of 58.12%. Given Athira Pharma's higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Mannatech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Mannatech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Athira Pharma has a net margin of 0.00% compared to Mannatech's net margin of -14.08%. Athira Pharma's return on equity of -107.06% beat Mannatech's return on equity.
Company Net Margins Return on Equity Return on Assets
Athira Pharma N/A -107.06% -89.89%
Mannatech -14.08% -398.35% -45.63%
: In the previous week, Mannatech had 1 more articles in the media than Athira Pharma. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.
Company Overall Sentiment
Athira Pharma Neutral
Mannatech Neutral
: Athira Pharma has a beta of 2.79, suggesting that its share price is 179% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Mannatech	$108.04M	0.09	-$15.21M	-$8.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Mannatech	-14.08%	-398.35%	-45.63%

Company	Overall Sentiment
Athira Pharma	Neutral
Mannatech	Neutral

Summary

Mannatech beats Athira Pharma on 7 of the 12 factors compared between the two stocks.

How does Mannatech compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

: Mannatech has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Skye Bioscience N/A N/A -$55.92M -$1.40 N/A
Mannatech $108.04M 0.09 -$15.21M -$8.00 N/A
: 21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 3.0% of Skye Bioscience shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Skye Bioscience has a net margin of 0.00% compared to Mannatech's net margin of -14.08%. Skye Bioscience's return on equity of -143.59% beat Mannatech's return on equity.
Company Net Margins Return on Equity Return on Assets
Skye Bioscience N/A -143.59% -119.89%
Mannatech -14.08% -398.35% -45.63%
: Skye Bioscience presently has a consensus price target of $9.80, indicating a potential upside of 1,017.19%. Given Skye Bioscience's stronger consensus rating and higher probable upside, research analysts clearly believe Skye Bioscience is more favorable than Mannatech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Skye Bioscience
1 Sell rating(s)
2 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.63
Mannatech
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: In the previous week, Skye Bioscience and Skye Bioscience both had 1 articles in the media. Skye Bioscience's average media sentiment score of 0.00 equaled Mannatech'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Skye Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Skye Bioscience has a beta of 3.03, suggesting that its stock price is 203% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.40	N/A
Mannatech	$108.04M	0.09	-$15.21M	-$8.00	N/A

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-143.59%	-119.89%
Mannatech	-14.08%	-398.35%	-45.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mannatech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Skye Bioscience beats Mannatech on 9 of the 14 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTEX vs. The Competition

Export

Metric	Mannatech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.42M	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-0.61	18.37	29.03	28.47
Price / Sales	0.09	281.03	476.10	60.92
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	-1.77	4.33	9.67	6.67
Net Income	-$15.21M	$72.19M	$3.55B	$332.53M
7 Day Performance	6.32%	2.02%	1.75%	2.03%
1 Month Performance	-15.72%	6.41%	5.66%	9.23%
1 Year Performance	-49.01%	37.69%	34.42%	39.62%

Mannatech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTEX Mannatech	0.1247 of 5 stars	$4.88 +2.7%	N/A	N/A	$9.42M	$108.04M	N/A	250	News Coverage Upcoming Earnings Gap Up
PLUR Pluri	2.5597 of 5 stars	$3.46 +2.5%	$12.00 +247.3%	N/A	$34.73M	$1.34M	N/A	150	Positive News Upcoming Earnings
CRVO CervoMed	3.468 of 5 stars	$3.71 -2.9%	$23.00 +519.9%	N/A	$34.36M	$4.01M	N/A	4	Upcoming Earnings
NXTC NextCure	2.2811 of 5 stars	$9.25 -3.8%	$23.00 +148.6%	N/A	$32.93M	N/A	N/A	90	News Coverage Upcoming Earnings Gap Up
ATHA Athira Pharma	N/A	$8.33 -3.4%	$4.00 -52.0%	N/A	$32.85M	N/A	N/A	40	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTEX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mannatech (MTEX) Competitors